HC Wainwright Begins Coverage on Polaryx Therapeutics (NASDAQ:PLYX)

Investment analysts at HC Wainwright assumed coverage on shares of Polaryx Therapeutics (NASDAQ:PLYX) in a note issued to investors on Thursday, Marketbeat.com reports. The firm set a “buy” rating and a $7.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 200.43% from the company’s current price.

Separately, Weiss Ratings upgraded Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Wednesday, July 1st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.50.

Polaryx Therapeutics Price Performance

Shares of PLYX stock opened at $2.33 on Thursday. The stock has a 50 day moving average price of $2.86. The company has a market cap of $109.58 million and a P/E ratio of -46.60. Polaryx Therapeutics has a 12 month low of $2.01 and a 12 month high of $48.91.

Polaryx Therapeutics (NASDAQ:PLYX) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.03) earnings per share for the quarter.

Insider Activity

In other news, CEO Alex Keun Mo Yang acquired 88,453 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was purchased at an average cost of $4.07 per share, for a total transaction of $360,003.71. Following the completion of the transaction, the chief executive officer directly owned 24,233,249 shares in the company, valued at $98,629,323.43. This trade represents a 0.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Key Stories Impacting Polaryx Therapeutics

Here are the key news stories impacting Polaryx Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Polaryx Therapeutics and set a $7.00 price target, signaling upside potential despite expected losses.
• Neutral Sentiment: The broker projected quarterly losses across upcoming periods, including Q2 2026 EPS of ($0.05), Q3 2026 EPS of ($0.06), and Q4 2026 EPS of ($0.06), highlighting that the company is still expected to remain unprofitable.
• Neutral Sentiment: HC Wainwright also forecast FY2026 EPS of ($0.22) and FY2027 EPS of ($0.28), which reflects ongoing investment and development-stage expenses rather than near-term profitability.
• Neutral Sentiment: Short interest data showed 0 shares reported as of July 10, indicating no meaningful short-interest pressure from the latest filing.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.